As of February 1991, the available data that have emerged from the few centers with sufficient experience in cardiac PET indicate that this promising and advanced imaging modality can often provide accurate information in both of these clinical situations. PET allows more sensitive data acquisition than single photon emission computed tomography (SPECT). In addition, coincidence detection provides a means of measuring tissue photon attenuation for subsequent correction of emission data. In clinical practice, such attenuation correction results in improved delineation of regional tracer concentration compared with current SPECT methods. Present-generation whole-body PET scanners provide multislice capabilities (up to 31 tomographic levels simultaneously) with an in-plane "Cardiac Positron Emission Tomography" was approved by the American Heart Association Steering Committee on February 14, 1991. Requests for reprints should be sent to the Office of Scientific Affairs, American Heart Association, 7320 Greenville Avenue, Dallas, TX 75231.
spatial resolution of 5-10 mm. In comparison, the resolution of tomographic thallium-201 studies using
SPECT is approximately [15] [16] [17] [18] [19] [20] Figure 3 shows that a PET score of grade 2 or more had a sensitivity of approximately 95% and a specificity of approximately 74% in identifying patients with reduced flow reserve by quantitative angiography (defined as a flow reserve of less than 3). This is consistent with sensitivity and specificity values in this same patient population reported in an earlier abstract (94% and 77%, respectively).15 When a higher threshold was chosen to define normal flow reserve by quantitative arteriography (flow reserve greater than or equal to 4), a higher specificity (95%) resulted. 15 As with any increase in normal threshold values resulting in increased specificity, it must be anticipated that a higher specificity will be achieved at the expense of a substantial reduction in sensitivity. According to the data in the abstract,15 the threshold resulting in a specificity of 95% was associated with abnormal results in 125 of 152 patients with coronary artery disease, yielding a sensitivity of 82%.
In the other large investigation, Go et al16 studied 202 patients with coronary arteriography and "2Rb Comparison With 20`T1 Scintigraphy PET has several theoretical advantages over 201 studies in the accurate identification of patients with coronary artery disease: PET provides higher resolution images with intrinsic collimation. The higher energy photons released from positron-emitting tracers and routine attenuation correction procedures overcome photon attenuation problems commonly encountered in 201T1 studies. However, in the first published paper comparing PET perfusion studies with exercise 201T1 scintigraphy in the same patients, the results were remarkably similar.12 Tamaki et al studied 51 patients (48 had coronary artery disease) by exercise`01T1 SPECT and PET performed with dipyridamole and ["N]ammonia. The sensitivity of 201T1 SPECT (96%) in identifying ischemia in patients with coronary artery disease was similar to that of PET (98%). Specificity in detecting disease could not be addressed because only three patients did not have coronary artery disease. Tamaki and colleagues also investigated the relative abilities of SPECT and PET to identify significant stenoses of individual coronary arteries. Again, the SPECT data (81% sensitivity and 94% specificity) compared favorably with the PET data (88% sensitivity and 90% specificity). Results of the PET studies were not significantly different in any vascular area from those of the SPECT studies.
Investigators at a second institution16 compared 20MT1 SPECT with 82Rb PET, using a single dipyridamole-hand grip stress for both imaging agents. They found improved diagnostic accuracy with 82Rb PET, results which stemmed primarily from lower sensitivity in the detection of coronary artery disease with 201T1 SPECT (76%) than with 82Rb PET (95%). The low sensitivity of 201T1 may be related in part to the timing of dipyridamole administration, because 82Rb was given at the peak dipyridamole effect, and`0'TI was given at least 6 minutes after the peak effect. It is also noteworthy that more than 75% of the falsenegative 201Tl SPECT studies that were correctly diagnosed on the 82Rb PET studies involved the inferior and posterior wall, a region with greater interpretative errors with 201Tl 
and identifying individual coronary artery stenoses (65% and 64%, respectively). It is important to note that in this study, PET'had higher specificity than SPECT both in diagnosis of patients (82% and 57%, respectively) and of individual coronary artery stenosis (92% and 84%, respectively). This could represent evidence of enhanced diagnostic accuracy of PET because of fewer interpretative errors related to photon attenuation. However, the low specificity of the '01T1 SPECT results in this study compared with previous 01T1 SPECT results raises the possibility that patient selection factors, such as a posttest referral bias (using an initial abnormal '01T1 test as the indication for subsequent coronary arteriography and PET), could be operative. 82Rb. Reversible and irreversible ischemic tissue injury may also be determined with 82Rb since uptake and retention of this agent is dependent on both coronary blood flow and cell membrane integrity. In regions of myocardial fibrosis, the diminished uptake of 82Rb reflects a reduction in perfusion that is more severe than in regions of dysfunctional but viable myocardium. In the setting of acute myocardial injury, uptake of 82Rb occurs if blood flow is restored, but leakage of 82Rb from necrotic tissue follows its initial uptake, resulting in a perfusion defect. In addition to net uptake, the kinetics of this ion leak may be used as an index of myocardial viability. [36] [37] [38] Recent data indicate that such an analysis may provide clinical information comparable to that achieved by PET imaging with FDG in patients with acute myocardial infarction.38
Comparison With 20'T1 Scintigraphy
The ability to define regional metabolic activity (and hence provide metabolic evidence of viable myocardium) by PET is unique. However, as noted above, imaging agents that reflect cation flux, such as 82Rb and 201Ti, may also provide clinically relevant information regarding myocardial viability. Because 20flT scintigraphy is more readily available than PET and is also less costly, it is important to compare the results of These data indicate that metabolic imaging using PET methods is superior to standard exercise-redistribution 201T1 scintigraphy in detection of viable myocardium in patients with left ventricular dysfunction.
Limitations of Comparative Studies
All four of these comparative studies involved small numbers of patients. Brunken et al reported data in only 12 patients in the initial study using planar 201T1 imaging techniques39 and in 26 patients in the later 20`TI SPECT analysis. 40 Tamaki et al41,42 also studied small numbers of patients (22 and 28, respectively) and it is possible that at least some of the same patients were included in both reports. None of the four studies included an independent standard of viability, such as improvement in wall motion after revascularization. There are two additional issues regarding analysis of the 20NT1 SPECT results in these four studies. First, the severity of the irreversible 201T1 defects was not considered in comparison with regional FDG activity. The level of relative 201T1 activity within irreversible defects may reflect tissue viability.44-46 Second, postexercise 201T1 imaging was used in all four studies and followed by only a single redistribution study [3] [4] PET provides a noninvasive means of identifying patients with coronary artery disease and left ventricular dysfunction who, on the basis of metabolic evidence of viability in the myocardial territory to be revascularized, may be candidates for coronary artery bypass surgery or angioplasty. PET also identifies patients (those without metabolic activity) in whom there is little chance for improvement in regional and global left ventricular function after revascularization and in whom the risks of revascularization may therefore not be justified.
The committee recommends that PET be used to assess relative regional metabolic activity with FDG in patients in whom myocardial viability is in question, but only in those patients in whom the identification of viable myocardium is an important clinical issue that will lead to changes in management, such as a decision regarding revascularization. Patients with coronary artery disease and regional or global left ventricular dysfunction are candidates for metabolic imaging with PET, particularly those in whom evidence of regional viability on a 20`TI perfusion study is equivocal.
The committee also recognizes and emphasizes that there are new insights regarding the use of 201T1 scintigraphy, including the use of resting 201T1 injections or exercise studies with 201T1 reinjection and/or late redistribution imaging, that hold promise. Comparative data in small numbers of patients suggest that 201T1 imaging may provide most of the clinically relevant data regarding viable myocardium in patients with left ventricular dysfunction. If this initial experience with 201T1 is confirmed by larger patient series, it may become reasonable, from the perspective of health care cost containment, to recommend that PET studies be performed only if an initial 201T1 study does not provide conclusive results.
The new 9'Tc perfusion agents may also be useful in detection of viable myocardium. Firm recommendations about the roles of 201T1 scintigraphy, 99mTc perfusion agents, or PET in identifying viable myocardium must await the results of definitive comparative studies. Implementation of multicenter trials comparing PET with conventional techniques for the definition of tissue viability, using standardized data acquisition and analysis, are recommended for objective assessment of the clinical efficacy of metabolic PET imaging.
